Mdxhealth is a commercial-stage precision diagnostics company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of prostate cancer and other urologic diseases. The Company’s tests are based on proprietary genetic, epigenetic and other complex molecular technologies.
Mdxhealth is dedicated to providing highly accurate and clinically actionable urologic solutions to inform patient diagnosis and treatment while improving healthcare economics for payers and providers.
Mdxhealth is listed on the Euronext and on NASDAQ under the ticker symbol MDXH.
Mdxhealth has been listed on Euronext since 2006 and on NASDAQ since 2021. There is only one class of shares in the company (common shares) and all shares have the same rights and voting representation. Other than American Depository Shares (ADS) listed on NASDAQ (each representing ten common shares) and stock options issued to employees, directors, and some consultants, there are no other financial instruments issued by the company.
The company reports its consolidated financial statements under International Financial Reporting Standards (IFRS) and all amounts are in US Dollars. Mdxhealth publishes a consolidated and audited Annual Report on an annual basis, a consolidated Interim Report for its June 30 half-year financial figures, and business/financial updates at the end of Q1 and Q3
Investor Relations Contact
For all investor related questions please call or email:
LifeSci Advisor (PR & IR)